Fund Mojo help you discover the best fund managers, funds, and related information

Fund Intelligence | Best Managers | JAGLX Insights | JAGLX Score | JAGLX Performance | JAGLX News | JAGLX Allocation | JAGLX Holdings Change

Janus Global Life Sciences T (JAGLX) Fund Ranking and Research

Ranking, Research and Recommendation of Janus Global Life Sciences T (JAGLX) Fund

    Last Trade: $55.34 on 6/23/2017, Change: +0.01 (0.02%)

 

Graph of Janus Global Life Sciences T Fund (JAGLX) ManagerFund Manager - Ethan Lovell

Fund Manager Information

Fund Manager Tenure: 1.5 years
Fund Family: Janus
Fund Category: Health
Fund Performance: May 30, 2016
Fundmojo Fund Grade: N/A (Score: *Manager is New*)     (What does this score mean?)

 

Graph of Janus Global Life Sciences T Fund (JAGLX) ProfileJanus Global Life Sciences T Fund (JAGLX) Profile

Fund Profile and Description

Janus Global Life Sciences T Fund seeks long-term growth of capital. Janus Global Life Sciences T Fund normally invests at least 80% of net assets in securities of companies that the portfolio manager believes have a life science orientation. It normally invests in issuers from several different countries, which may include the United States. Janus Global Life Sciences T Fund may, under unusual circumstances, invest in a single country. It normally invests at least 25% of total assets in the "life sciences" sector, which may include companies in the following industry groups: health care; pharmaceuticals; agriculture; cosmetics/personal care; and biotechnology. Janus Global Life Sciences T Fund may invest assets in derivatives.

 

Janus Global Life Sciences T (JAGLX) Fund Strength What we like about Janus Global Life Sciences T (JAGLX) Fund

Data for Janus Global Life Sciences T Fund (JAGLX) as of May 30, 2016

  • Janus Global Life Sciences T Fund (JAGLX) has good mid-term performance (3-year return 19.39% vs 15.21% Health category median performance)
  • Janus Global Life Sciences T Fund (JAGLX) has good Long-term performance (5-year return 19.37% vs 16.08% Health category median performance)
  • Janus Global Life Sciences T Fund (JAGLX) ratio of up-years vs down years is greater than 2
  • Janus Global Life Sciences T Fund (JAGLX) has a Morningstar rating of 4 and above
  • Janus Global Life Sciences T Fund (JAGLX) has a lower expense ratio than its Health average: 0.95% vs 1.32%
  • Janus Global Life Sciences T Fund (JAGLX) is a true no-load fund as it has no load and no 12b1 promotion, distributions, marketing expenses

Janus Global Life Sciences T Fund (JAGLX) Weakness What we are cautious about Janus Global Life Sciences T (JAGLX) Fund

Data for Janus Global Life Sciences T Fund (JAGLX) as of May 30, 2016

  • Janus Global Life Sciences T Fund (JAGLX) management has been with Janus Global Life Sciences T Fund for only 1.5 years, it is hard to judge manager's ability based on this fund's operation record
  • Janus Global Life Sciences T Fund (JAGLX) has a less-than-ideal short-term performance (1-year return -15.83% vs -12.93% Health category median performance)
  • Janus Global Life Sciences T Fund (JAGLX) has an annual stock turnover rate of 47.00% that is higher than the Health average of 43.99%. This could mean Janus Global Life Sciences T is more nimble, but also signal potential high tax impact and high trading fees
  • Janus Global Life Sciences T Fund (JAGLX) is more volatile than its peers as it has a 3-year Standard Deviation of 17.78 that is higher than category average of 17.59
  • As a Health focused fund, Janus Global Life Sciences T Fund (JAGLX) is less diversified and has inherited sector risks associated with the fund
See Janus Global Life Sciences T Fund (JAGLX) performance details as of May 30, 2016

 

What do you think?

 

Compare Janus Global Life Sciences T Fund (JAGLX)Compare with other top Health category mutual funds

Aadditional top Health mutual funds for your consideration

FundYear to Date1 Year3 year5 year
Janus Global Life Sciences T-7.78-15.8319.3919.37
Fidelity Advisor Health Care A (FACDX)-5.84-13.4918.7717.80Compare
Hartford Healthcare A (HGHAX)-6.82-7.8017.3816.39Compare
AllianzGI Health Sciences A (RAGHX)-4.62-9.3315.8113.50Compare

See top fund managers for Health Category Funds

 

Compare Janus Global Life Sciences T Fund (JAGLX)Compare with Health category ETFs

Some Health ETFs for your consideration

ETFYear to DateOne YearThree Year
First Trust NYSE Arca Biotech ETF (FBT)000
SPDR S&P Health Care Equipment ETF (XHE)000
SPDR S&P Biotech ETF (XBI)000
PowerShares S&P SmallCap Health Care ETF (PSCH)000
PowerShares Dynamic Pharmaceuticals ETF (PJP)000

 

Graph of Janus Global Life Sciences T Fund (JAGLX) Net Asset TrackingJanus Global Life Sciences T (JAGLX) Fund Net Asset

Track net asset change of Janus Global Life Sciences T fund (JAGLX)

DateNet Asset
05/2016$3.91B
03/2016$3.73B
02/2016$3.93B
More historic net asset information on Janus Global Life Sciences T Fund (JAGLX)

  

Graph of Janus Global Life Sciences T Fund (JAGLX) Portfolio TrackingJanus Global Life Sciences T (JAGLX) Fund Portfolio Allocation

Track portfolio allocation change of Janus Global Life Sciences T fund (JAGLX)

DateCashStockBondOther
03/20160.91%96.85%0%1.98%
12/20151.46%95.99%0%2.03%
09/20150.9%91.41%0%7.16%
Click here to see more historic asset allocation information on Janus Global Life Sciences T Fund (JAGLX)

 

graph of Janus Global Life Sciences T Fund (JAGLX) Top 10 Position TrackingTop 10 Holdings in Janus Global Life Sciences T (JAGLX) Fund

Discover what Janus Global Life Sciences T Fund (JAGLX) manager is buying

Mar 30, 2016
Allergan plc Ordinary Shares [3.79%]
Amgen Inc. [3.76%]
AbbVie Inc. Common Stock [3.2%]
Celgene Corporation [3.09%]
Bristol-Myers Squibb Company Co [2.72%]
Boston Scientific Corporation C [2.72%]
Aetna Inc. Common Stock [2.67%]
Teva Pharmaceutical Industries [2.49%]
Sanofi SA [2.46%]
Universal Health Services, Inc. [2.38%]

Dec 30, 2015
Amgen Inc. [3.82%]
AbbVie Inc. Common Stock [3.1%]
Celgene Corporation [2.74%]
Allergan plc Ordinary Shares [2.72%]
Teva Pharmaceutical Industries [2.67%]
Aetna Inc. Common Stock [2.47%]
Sanofi SA [2.39%]
Bristol-Myers Squibb Company Co [2.36%]
Boston Scientific Corporation C [2.32%]
Eli Lilly and Company Common St [2.31%]

Sep 29, 2015
Amgen Inc. [3.5%]
AbbVie Inc. Common Stock [2.75%]
Sanofi [2.7%]
VALEANT PHARMACEUTICALS INTL IN [2.56%]
Johnson & Johnson Common Stock [2.49%]
Celgene Corporation [2.47%]
Aetna Inc. Common Stock [2.42%]
Allergan plc Ordinary Shares [2.36%]
Biogen Inc. [2.35%]
Teva Pharmaceutical Industries [2.32%]
Click here for Stock Holding Change Map in Janus Global Life Sciences T Fund (JAGLX)

  

Latest News on Janus Global Life Sciences T (JAGLX) Fund

See what is happening with Janus Global Life Sciences T Fund (JAGLX)

 

Janus Global Life Sciences T Fund (JAGLX) Related ResourcesSee more information on Janus Global Life Sciences T (JAGLX) Fund

Popular pages on Janus Global Life Sciences T (JAGLX) Fund

  

Fund Mojo Newsletter

Fund Mojo on Facebook Follow FundMojo on Twitter Fund Update